Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss. The study aims to assess the safety, effectiveness, and tolerability of upadacitinib in treating severe alopecia areata (AA) in Japan, a condition where the immune system attacks hair follicles.
The intervention being tested is upadacitinib, an approved drug, administered in oral tablet form. It is being evaluated for its potential to treat AA by comparing its effects to a placebo.
This interventional study is randomized and employs a parallel assignment model with double masking, meaning neither participants nor investigators know who receives the drug or placebo. The primary purpose is treatment-focused.
The study began on June 19, 2025, with a primary completion date yet to be determined. The latest update was submitted on July 22, 2025, indicating the study is currently recruiting participants.
The outcome of this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if upadacitinib proves effective in treating AA. It could also influence the competitive landscape in the pharmaceutical industry, where effective treatments for AA are in demand.
The study is ongoing, with further details available on the ClinicalTrials portal.